Synthetic peptide and application thereof

A technology for synthesizing polypeptides and amino acids, applied in the field of medicine, can solve the problems of inability to respond to infants and young children with pneumococcal polysaccharide vaccine, unable to achieve protective effect, incomplete development of immune system, etc., and achieve easy mass production and good bacteriostatic effect. , the effect of low cost

Active Publication Date: 2018-06-15
SOUTHWEST MEDICAL UNIVERISTY
View PDF6 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The current immunized Streptococcus pneumoniae vaccine mainly consists of serotype-dependent vaccines such as 23-valent capsular polysaccharide vaccine and 7-valent protein-polysaccharide conjugate vaccine, which can only contain about 80% of the circulating serotypes and cannot achieve complete protection.
In addition, due to the incomplete development of the immune system of newborns, pneumococcal polysaccharide vaccines cannot elicit immune responses in infants, nor can they induce immune memory
On the other hand, due to the extensive and irregular use of antibiotics, the emergence of multi-drug-resistant Streptococcus pneumoniae strains worldwide has also been found in China carrying penicillin-binding protein (pbp) variants and multiple transpositions such as Tn916 type The multidrug-resistant lung chain strains of children have also brought greater challenges to clinical anti-infective treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synthetic peptide and application thereof
  • Synthetic peptide and application thereof
  • Synthetic peptide and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Based on the existing choline-binding sequence, combined with Swiss-Model online software for structural analysis, a synthetic polypeptide was designed, the amino acid sequence of which is shown in SEQ ID No.1;

[0040] SEQ ID No. 1: TGWVKDNGSWYYLNLSGYML.

[0041] (Thr-Gly-Trp-Val-Lys-Asp-Asn-Gly-Ser-Trp-Tyr-Tyr-Leu-Asn-Leu-Ser-Gly-Tyr-Met-Leu)

Embodiment 2

[0043] Preparation of Synthetic Peptides

[0044]Amino acid-King resin was selected as the carrier 2-Cl-Resin as the carrier (resin) for polypeptide synthesis, the resin was fully swollen with dichloromethane, washed several times with dichloroformamide, and the Fmoc-protecting group was condensed with an appropriate concentration of DBLK Then, wash it several times with dimethylformamide, wash away DBLK, and weigh an appropriate amount of condensing agent benzotriazole-N, N, N', N'-tetramethyluronium hexafluorophosphate and activator Methylmorpholine and the second Fmoc-protected amino group (Fmoc-Pro-OH) at the C-terminal (Fmoc-Pro-OH) are coupled, and the ninhydrin detection method is used to detect that the connection is relatively complete. Wash several times with dimethylformamide and wash away Remaining various residues, activators and condensing agents are coupled according to the amino acid sequence. After all the amino acids are connected, the last Fmoc-protecting gr...

Embodiment 3

[0046] Cytotoxicity

[0047] Experimental method: When the normally cultured 293T cells were cultured to a confluence of about 90%, they were trypsinized and inoculated into a 96-well cell culture plate, and the culture system was 100 μl DMEM high-glucose medium (containing 10% serum and 1% double antibody). 10 μL, 5 μL, 2.5 μL, 1 μL, 0.1 μL of the synthetic polypeptide of the present invention (1 mg / mL) was added to the medium before the cells were attached to the wall in the first vertical row of 5 wells. Add 10 μL, 5 μL, 2.5 μL, 1 μL, 0.1 μL of the synthetic polypeptide of the present invention (1 mg / mL) to the second vertical row of 5 wells immediately after wall attachment. One well in each row was reserved as a control. The cells were cultured overnight in a carbon dioxide incubator at 37°C, and the state of the cells was observed.

[0048] Experimental results: The growth status of the treated cells in each group was normal, the growth speed was similar, and no cell l...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a synthetic peptide. The synthetic peptide comprises: (a) the amino acid sequence of the synthetic peptide is shown as in SEQ ID No.1; (b) one or more amino acids of a peptideis / are deleted, inserted or replaced in the synthetic peptide defined by the (a), and the peptide derived from (a) has the same biological function with the peptide. The synthetic peptide is designedin combination with the structure analysis of Swiss-Model online software according to the known choline combination sequence. The synthetic peptide has the characteristic of combination with the choline molecule on the surface of streptococcus pneumoniae, and has the capabilities of inhibiting growth and promoting autolysis of the streptococcus pneumoniae. The synthetic peptide is non-toxic and has a certain application potential.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a synthetic polypeptide and its application. Background technique [0002] Streptococcus pneumoniae (Streptococcus pneumoniae) belongs to Firmicutes - Streptococcus is a Gram-positive coccus widely distributed in nature and often lives in the nasopharyngeal cavity of normal people. Streptococcus pneumoniae is an opportunistic pathogen that develops when the host's immunity is weakened. It is the main pathogen causing diseases such as community-acquired pneumonia, bronchitis, sinusitis, otitis media, sepsis and meningitis. Newborns and people with low immunity are high-risk groups for Streptococcus pneumoniae infection, and more than 1 million children younger than 5 years old die of Streptococcus pneumoniae-related invasive diseases every year. [0003] Streptococcus pneumoniae has a capsule, and the polysaccharide of the capsule is the main pathogenic factor of Streptococcus ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/08A61K38/10A61P31/04
CPCA61K38/00C07K7/08
Inventor 张志坤周英顺
Owner SOUTHWEST MEDICAL UNIVERISTY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap